Biosimilars News
The US Food and Drug Administration approved 50 novel drugs in 2024, continuing to outpace its global regulatory peers. 10 January 2025
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Drug development consultancy Certara has published a report on the Inflation Reduction Act’s (IRA) impact on oncology biosimilar uptake. 29 August 2024
Exclusive
Company Spotlight
"Umoja Biopharma, Inc. is a pre-clinical stage biotechnology company located in Seattle WA. Founded based on pioneering work performed at Seattle Children's Research Institute and Purdue University, Umoja is advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo."
Most Read
4 December 2024
In Brief
Korean company Samsung Biologics has signed a production agreement with an unidentified large US pharma corporation worth more than $1.06 billion. 3 July 2024
Mergers and Acquisitions
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
25 September 2023
24 August 2023
21 August 2023
16 June 2022
30 March 2022
Editor's Pick
Boardroom
Samsung Bioepis has appointed Kyung-Ah Kim as its new president and chief executive, succeeding Christopher Hansung Ko, who will lead the Samsung Future Business Division. 27 November 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Swiss pharma giant Novartis’s board of directors announced today the appointment of Gilbert Ghostine as chairman-designate of the new board of Sandoz, its biosimilars and generics business. 20 February 2023
The American business of South Korea's Celltrion Healthcare has appointed Thomas Nusbickel as chief commercial officer. 7 February 2023
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze